Company Profile

Thermimage Inc
Profile last edited on: 6/22/16      CAGE:       UEI:

Business Identifier: radiometric temperature measurement system, a technology providing direct temperature measurement of tissues deep within the body.
Year Founded
2007
First Award
2013
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1194 West 4800 South
Salt Lake City, UT 84127
   (801) 207-8280
   info@thermimage.com
   www.thermimage.com
Location: Single
Congr. District: 02
County: Salt Lake

Public Profile

Thermimage Inc has developed and commercialized a new proprietary platform technology called MicroSense, which will provide safe and comfortable noninvasive measurement of tissue temperature 5-7 centimeters deep within the body. The firm has developed two devices incorporating this technology, both of which can passively detect minute amounts of microwave energy generated by body heat and convert the signals into temperature measurements. Thermimage has chosen to commercialize two devices using this technology. The first device is the AccuCor Deep Tissue Monitoring System (DTMS), designed to monitor brain tissue temperature in cardiac surgery patients and patients in neurological intensive care units. This system is expected to gain rapid acceptance for monitoring and managing patients placed on a heart-lung machine for cardiac surgery, patients undergoing induced hypothermia for any reason, patients in neurological ICUs, patients in pediatric and neonatal ICUs, patients presenting in emergency departments, and many patients undergoing non-cardiac surgery. The company estimates the total worldwide market potential for this application to be in excess of $3.5 billion. The second device is the Thermaflux Scanner, a safe and non-invasive means of diagnosing pediatric Vesicoureteral Reflux (VUR), a condition in which bladder urine flows back up into the kidneys, exposing them to infection and potential lifelong health problems. Using the most conservative published VUR incidence rate of one percent, there are more than 840,000 new cases of VUR diagnosed annually. The company estimates the total worldwide market potential for this application to be in excess of $1.0 billion.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 2 NIH $1,552,780
Project Title: Accutemp Sensor: Radiometry Based Non-Invasive Continuous Core Body Temperature M

Key People / Management

  Douglas G Turnquist -- President & CEO

  Phillip J Carter -- Vice President of Marketing and Sales

  Douglas O Reudink -- Vice President of Research and Development

  Brent W Snow -- Chief Technology Officer

Company News

There are no news available.